Atea Pharmaceuticals, Inc. (AVIR) › Cash & EquivalentsAtea Pharmaceuticals, Inc. (AVIR) — Cash & EquivalentsAnnual figures by fiscal year, from SEC filings.2018: $34.49M2019: $21.66M2020: $850.12M2021: $764.38M2022: $188.46M2023: $143.82M2024: $64.70M2025: $95.71M$95.71M2018Cash & Equivalents (USD)2025Fiscal YearCash & EquivalentsChange YoY2025$95.71M+47.9%2024$64.70M-55.0%2023$143.82M-23.7%2022$188.46M-75.3%2021$764.38M-10.1%2020$850.12M+3824.6%2019$21.66M-37.2%2018$34.49M—Other metrics: RevenueCost of RevenueGross ProfitOperating IncomeNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesShareholders' EquityOperating Cash FlowCapital ExpendituresShares OutstandingDividends Per Share